Syndax Pharmaceuticals (SNDX) – Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for Syndax Pharmaceuticals (NASDAQ: SNDX):

• 10/13/2026 – Syndax Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $38.00 price target on the stock.
• 10/2/2026 – Syndax Pharmaceuticals was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 10/1/2026 – Syndax Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright.
• 10/1/2026 – Syndax Pharmaceuticals had its “buy” rating reaffirmed by UBS Group AG.
• 9/29/2026 – Syndax Pharmaceuticals had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $35.00 price target on the stock.
• 9/16/2026 – Syndax Pharmaceuticals was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 8/21/2026 – Syndax Pharmaceuticals was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 8/21/2026 – Syndax Pharmaceuticals had its price target lowered by UBS Group AG from $37.00 to $33.00. They now have a “buy” rating on the stock.

Syndax Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company’s research programs target biological pathways involved in malignancy and immune-related conditions, with an emphasis on medicines that may address significant unmet medical needs.

Syndax’s lead product, Revuforj (revumenib), is an oral menin inhibitor approved by the U.S. Food and Drug Administration for treating relapsed or refractory acute leukemia with a KMT2A translocation in adults and pediatric patients aged one year and older.